# A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects

> **NCT01359163** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 20 (actual)

## Conditions studied

- Therapeutic Equivalency

## Interventions

- **DRUG:** etynodiol diacetate
- **DRUG:** etynodiol diacetate

## Key facts

- **NCT ID:** NCT01359163
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359163, "A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT01359163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*